Literature DB >> 27601021

Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study.

Chrysoula G Liakou1, George Mastorakos2, Konstantinos Makris3, Ioannis G Fatouros4, Alexandra Avloniti5, Helen Marketos3, Julia D Antoniou6, Antonios Galanos6, Ismene Dontas6, Demetrios Rizos7, Symeon Tournis6.   

Abstract

Studies in postmenopausal women have identified sclerostin as a strong candidate for mediating estrogen effects on the skeleton. The effects of estradiol on sclerostin and Dickkopf-1 in younger women remain unclear. The main purpose of this study is to investigate the impact of estradiol and gonadotrophins fluctuations during the menstrual cycle on circulating sclerostin and Dickkopf-1 levels and the possible relationship of sclerostin and Dickkopf-1 with changes in N-terminal propeptide of type 1 collagen and C-telopeptide of collagen cross-links. Fourteen healthy premenopausal Caucasian women, with regular menses, aged 33.6 ± 4.5 years participated. After the first day of menstruation and every-other-day up to the next menses, fasting serum estradiol, luteinizing hormone, follicle-stimulating hormone, sclerostin, Dickkopf-1, N-terminal propeptide of type 1 collagen, and C-telopeptide of collagen cross-links levels were measured in peripheral blood. Participants completed dietary questionnaires and the International physical activity questionnaire during the cycle. Neither sclerostin nor Dickkopf-1 levels changed significantly across the menstrual cycle (p = 0.18 and p = 0.39, respectively), while N-terminal propeptide of type 1 collagen and C-telopeptide of collagen cross-links levels presented cyclic variation (p < 0.001 and p = 0.004, respectively). Baseline sclerostin (29.23 ± 10.62 pmol/L) positively correlated with N-terminal propeptide of type 1 collagen (r = 0.71, p < 0.01) and C-telopeptide of collagen cross-links (r = 0.63, p < 0.05), while Dickkopf-1 (4.82 ± 2.23 pmol/L) correlated positively with N-terminal propeptide of type 1 collagen (r = 0.56, p < 0.05). Mid-cycle E2 levels presented significant negative association with the percent decrease of C-telopeptide of collagen cross-links at all-time points during the luteal period (r = -0.60 to -0.68, p < 0.05-0.01). Circulating sclerostin and Dickkopf-1 levels do not change across the menstrual cycle and do not demonstrate any relationship with estradiol in premenopausal women. Further investigation is needed concerning the role of sclerostin and Dickkopf-1 on bone turnover in young estrogen-sufficient women.

Entities:  

Keywords:  Bone turnover markers; Dkk-1; Estradiol; Sclerostin

Mesh:

Substances:

Year:  2016        PMID: 27601021     DOI: 10.1007/s12020-016-1056-9

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  37 in total

1.  Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass.

Authors:  Frederic Morvan; Kim Boulukos; Philippe Clément-Lacroix; Sergio Roman Roman; Isabelle Suc-Royer; Béatrice Vayssière; Patrick Ammann; Patrick Martin; Sonia Pinho; Philippe Pognonec; Patrick Mollat; Christof Niehrs; Roland Baron; Georges Rawadi
Journal:  J Bone Miner Res       Date:  2006-06       Impact factor: 6.741

2.  Changes in biochemical markers of osteoblastic activity during the menstrual cycle.

Authors:  H K Nielsen; K Brixen; R Bouillon; L Mosekilde
Journal:  J Clin Endocrinol Metab       Date:  1990-05       Impact factor: 5.958

3.  Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats.

Authors:  Feng-Sheng Wang; Jih-Yang Ko; Chun-Liang Lin; Hsing-Long Wu; Huei-Jin Ke; Pei-Ju Tai
Journal:  Bone       Date:  2006-10-20       Impact factor: 4.398

4.  Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women.

Authors:  Faryal S Mirza; I Desmond Padhi; Lawrence G Raisz; Joseph A Lorenzo
Journal:  J Clin Endocrinol Metab       Date:  2010-02-15       Impact factor: 5.958

Review 5.  Clinical utility of serum sclerostin measurements.

Authors:  Bart L Clarke; Matthew T Drake
Journal:  Bonekey Rep       Date:  2013-06-05

6.  Cyclic variations of bone resorption mediators and markers in the different phases of the menstrual cycle.

Authors:  Bruno Mozzanega; Salvatore Gizzo; Daniela Bernardi; Luigi Salmaso; Tito Silvio Patrelli; Roberto Mioni; Livio Finos; Giovanni Battista Nardelli
Journal:  J Bone Miner Metab       Date:  2013-03-12       Impact factor: 2.626

7.  Effect of micronized progesterone on bone turnover in postmenopausal women on estrogen replacement therapy.

Authors:  G Azizi; A Hansen; K M Prestwood
Journal:  Endocr Res       Date:  2003-05       Impact factor: 1.720

8.  Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women.

Authors:  Claire Durosier; Antoon van Lierop; Serge Ferrari; Thierry Chevalley; Socrates Papapoulos; René Rizzoli
Journal:  J Clin Endocrinol Metab       Date:  2013-07-17       Impact factor: 5.958

9.  Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin.

Authors:  Alexander G Robling; Paul J Niziolek; Lee A Baldridge; Keith W Condon; Matthew R Allen; Imranul Alam; Sara M Mantila; Jelica Gluhak-Heinrich; Teresita M Bellido; Stephen E Harris; Charles H Turner
Journal:  J Biol Chem       Date:  2007-12-17       Impact factor: 5.157

10.  Relation of age, gender, and bone mass to circulating sclerostin levels in women and men.

Authors:  Ulrike I Mödder; Kelley A Hoey; Shreyasee Amin; Louise K McCready; Sara J Achenbach; B Lawrence Riggs; L Joseph Melton; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2011-02       Impact factor: 6.741

View more
  5 in total

Review 1.  Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles.

Authors:  Giovanni Lombardi; Mosè Barbaro; Massimo Locatelli; Giuseppe Banfi
Journal:  Endocrine       Date:  2017-02-08       Impact factor: 3.633

2.  Menstrual Cycle Related Fluctuations in Circulating Markers of Bone Metabolism at Rest and in Response to Running in Eumenorrheic Females.

Authors:  Anne Guzman; Nigel Kurgan; Sara C Moniz; Seth F McCarthy; Craig Sale; Heather Logan-Sprenger; Kirsty J Elliott-Sale; Tom J Hazell; Panagiota Klentrou
Journal:  Calcif Tissue Int       Date:  2022-04-16       Impact factor: 4.000

Review 3.  Hormonal and systemic regulation of sclerostin.

Authors:  Matthew T Drake; Sundeep Khosla
Journal:  Bone       Date:  2016-12-10       Impact factor: 4.398

4.  Gender-Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen.

Authors:  Mariska C Vlot; Chantal M Wiepjes; Renate T de Jongh; Guy T'Sjoen; Annemieke C Heijboer; Martin den Heijer
Journal:  J Bone Miner Res       Date:  2019-08-19       Impact factor: 6.741

5.  Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy.

Authors:  Kristina Bojanić; Ines Bilić Ćurčić; Lucija Kuna; Tomislav Kizivat; Robert Smolic; Nikola Raguž Lučić; Kristina Kralik; Vatroslav Šerić; Gordana Ivanac; Sandra Tucak-Zorić; Aleksandar Včev; Martina Smolić
Journal:  J Clin Med       Date:  2018-09-17       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.